SeqLL, LLC today announced the launch of the tSMS System Early Access
Program giving researchers priority access to its proprietary
quantitative sequencing platform. This benchtop system has been designed
to deliver unparalleled quantitative RNA and specialty DNA sequencing
results to both academic and industry research partners. tSMS has the
capacity to detect low-fold changes and discover rare transcripts that
are missedby other sequencing methods and address challenging
samples such as FFPE/degraded samples and ultra-low input samples. The
SeqLL tSMS platform is the first to offer Direct RNA Sequencing (DRS™)
“We believe that our Early Access Program will allow research partners to gain experience with the power of tSMS technology to discover what their current sequencing approaches are missing,” states Elizabeth Reczek, Ph.D., CEO at SeqLL. "Our vision is to bring this proprietary, amplification-free technology to market in mid-2017, backed by a commitment to unsurpassed customer support and uncompromising quality.”
About the Early Access Program
SeqLL’s Early Access Program will run from October 2016 through early 2017. SeqLL is now seeking collaborators to field test beta versions of the system. Data generated from the Early Access Program will be used to optimize the ease of use and training materials in support of the mid-2017 commercial launch of the tSMS Benchtop System. Priority will be given to collaborators with a near term research project that would benefit from the unique capabilities of the tSMS platform to generate superior and/or complimentary results to other sequencing approaches.
SeqLL’s exclusive true Single Molecule Sequencingplatform enables direct parallel sequencing of millions of individual molecules. This novel amplification-free technology precisely reflects sample composition without bias and loss of diversity via a simple, integrated workflow and benchtop instrument design. In contrast with other technologies, sample preparation is minimized to as little as 3 steps. tSMScan deliver linear quantification over a 5-log range and sensitivity to 1.3-1.5-fold differences in expression levels. It is ideal for fragment sizes as low as 50 base pairs and can yield valuable data from even picogram-level input.
Located in Woburn, MA, SeqLL, LLC was founded in 2013 to bring a new breed of next generation sequencing technology, true Single Molecule Sequencing (tSMS), to the research and healthcare communities. SeqLL currently offers its amplification-free transcriptome profiling, specialty DNA analysis and bioinformatics on a service basis.
For more information, please visit www.SeqLL.com.
For the Early Access Program: email@example.com.
All products are for research use only and are not intended for diagnostic uses.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161019005801/en/Business Wire
Last updated on: 19/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.